|
Norbert G. Riedel Ph.D. is corporate vice president and chief scientific officer of Baxter International Inc. having served in that capacity since March 2001. He joined Baxter in 1998 as president of the recombinant unit within Baxter's BioScience business. Prior to joining Baxter he was head of worldwide biotechnology and worldwide core research functions at Hoechst Marion Roussel now Sanofi-Aventis.
Dr. Riedel received his Ph.D. in biochemistry from the University of Frankfurt in 1983. He was a postdoctoral fellow at Harvard University from 1984 to 1987 assistant professor and associate professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991 and a visiting professor at Massachusetts Institute of Technology in 1992. He remains affiliated with Boston University as an adjunct professor and also serves as an adjunct professor of medicine at Northwestern University's Feinberg School of Medicine.
Dr. Riedel serves on the board of directors of Oscient Pharmaceuticals Corporation and Medigene AG. He is a member of the board of directors of the Illinois Biotechnology Industry Organization and a member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology.
Baxter International Inc. through its subsidiaries assists healthcare professionals and their patients with treatment of complex medical conditions including cancer hemophilia immune disorders kidney disease and trauma. The company applies its expertise in medical devices pharmaceuticals and biotechnology to make a meaningful difference in patients' lives. | 